Answers are grounded in this paper and cite their sources.
The use of peptides in pharmaceutical applications is always hindered by the rapid degradation of the peptides by enzymes. Recent work on β-peptides, peptides constructed entirely from β-amino acids, has shown that even the short-chain oligomers (6 or 7 residues) exhibit remarkably stable secondary structures. However, before certain applications of β-peptides can be considered, an information about their possible interactions or reactions with enzymes must be acquired.Ames tests (all negative) have now been performed on a selection of β-amino acids, which would be the result of the enzymatic degradation of a β-peptide. Furthermore, digestion experiments using a variety of peptidases and β-peptides have now shown that β-peptides, in sharp contrast to their α-peptide counterparts, undergo no degradation.
No takes yet. Share an insight, caveat, or question.
Hintermann et al. (1997) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: